Literature DB >> 10658977

Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function.

M C Mingari1, M Ponte, C Vitale, R Bellomo, L Moretta.   

Abstract

Different families of major histocompatibility complex (MHC)-specific inhibitory receptors (NKRs) play a major role in natural killer (NK) cell function, allowing discrimination between normal cells and cells that do not express adequate amounts of MHC class I antigens. This occurs in most instances as a consequence of viral infection or tumor transformation. In T lymphocytes, expression of NKR is mostly confined to activated CD8+ cytolytic T lymphocytes (CTLs). While NKR expression by CTLs may be viewed as a mechanism preventing damages to normal cells by those CTLs that have acquired NK-like activity, it may also down regulate TCR-mediated T cell activation, thus, impairing CTL functions. The finding that certain cytokines can modulate killer inhibitory receptor expression in CTLs is of major interest and might be instrumental in novel therapeutic approaches aimed at the down regulation ofT-cell function in transplantation or autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10658977     DOI: 10.1016/s0198-8859(99)00158-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

Review 1.  ITAMs versus ITIMs: striking a balance during cell regulation.

Authors:  Daniel D Billadeau; Paul J Leibson
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  CD8⁺ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung.

Authors:  Berber Piet; Godelieve J de Bree; Barbara S Smids-Dierdorp; Chris M van der Loos; Ester B M Remmerswaal; Jan H von der Thüsen; Jan M W van Haarst; Jan P Eerenberg; Anja ten Brinke; Wim van der Bij; Wim Timens; René A W van Lier; René E Jonkers
Journal:  J Clin Invest       Date:  2011-05-02       Impact factor: 14.808

Review 3.  The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors.

Authors:  Gabriella Pietra; Chiara Romagnani; Claudia Manzini; Lorenzo Moretta; Maria Cristina Mingari
Journal:  J Biomed Biotechnol       Date:  2010-06-22

4.  Polymorphisms of killer immunoglobulin-like receptors (KIRs) and HLA ligands in northeastern Thais.

Authors:  Suwit Chaisri; Kriengkrai Kitcharoen; Amornrat V Romphruk; Arunrat Romphruk; Campbell S Witt; Chanvit Leelayuwat
Journal:  Immunogenetics       Date:  2013-06-29       Impact factor: 2.846

5.  Positive psychosocial factors and NKT cells in ovarian cancer patients.

Authors:  Donald M Lamkin; Susan K Lutgendorf; Stephanie McGinn; Minh Dao; Heena Maiseri; Koen DeGeest; Anil K Sood; David M Lubaroff
Journal:  Brain Behav Immun       Date:  2007-07-23       Impact factor: 7.217

6.  Protective genotypes in HIV infection reflect superior function of KIR3DS1+ over KIR3DL1+ CD8+ T cells.

Authors:  Katrin Zipperlen; Maureen Gallant; Staci Stapleton; John Heath; Lisa Barrett; Michael Grant
Journal:  Immunol Cell Biol       Date:  2014-08-12       Impact factor: 5.126

7.  Divide, Conquer, and Sense: CD8+CD28- T Cells in Perspective.

Authors:  Fernando A Arosa; André J Esgalhado; Carolina A Padrão; Elsa M Cardoso
Journal:  Front Immunol       Date:  2017-01-03       Impact factor: 7.561

8.  Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation.

Authors:  Min Wang; Dirk Windgassen; Eleftherios T Papoutsakis
Journal:  BMC Genomics       Date:  2008-05-16       Impact factor: 3.969

9.  Squamous tissue lymphocytes in the esophagus of controls and patients with reflux esophagitis and Barrett's esophagus are characterized by a non-inflammatory phenotype.

Authors:  Alexandra Lind; Leo Koenderman; Johannes G Kusters; Peter D Siersema
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.